Assaying the effect of levodopa on the evaluation of risk in healthy humans.

In humans, dopamine is implicated in reward and risk-based decision-making. However, the specific effects of dopamine augmentation on risk evaluation are unclear. Here we sought to measure the effect of 100 mg oral levodopa, which enhances synaptic release of dopamine, on choice behaviour in healthy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mkael Symmonds, Nicholas D Wright, Elizabeth Fagan, Raymond J Dolan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/77b8e3e653ee486e9a0f48ed4d20fcd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77b8e3e653ee486e9a0f48ed4d20fcd7
record_format	dspace
spelling	oai:doaj.org-article:77b8e3e653ee486e9a0f48ed4d20fcd72021-11-18T07:38:45ZAssaying the effect of levodopa on the evaluation of risk in healthy humans.1932-620310.1371/journal.pone.0068177https://doaj.org/article/77b8e3e653ee486e9a0f48ed4d20fcd72013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23844168/?tool=EBIhttps://doaj.org/toc/1932-6203In humans, dopamine is implicated in reward and risk-based decision-making. However, the specific effects of dopamine augmentation on risk evaluation are unclear. Here we sought to measure the effect of 100 mg oral levodopa, which enhances synaptic release of dopamine, on choice behaviour in healthy humans. We use a paradigm without feedback or learning, which solely isolates effects on risk evaluation. We present two studies (n = 20; n = 20) employing a randomised, placebo-controlled, within-subjects design. We manipulated different dimensions of risk in a controlled economic paradigm. We test effects on risk-reward tradeoffs, assaying both aversion to variance (the spread of possible outcomes) and preference for relative losses and gains (asymmetry of outcomes--skewness), dissociating this from potential non-specific effects on choice randomness using behavioural modelling. There were no systematic effects of levodopa on risk attitudes, either for variance or skewness. However, there was a drift towards more risk-averse behaviour over time, indicating that this paradigm was sensitive to detect changes in risk-preferences. These findings suggest that levodopa administration does not change the evaluation of risk. One possible reason is that dopaminergic influences on decision making may be due to changing the response to reward feedback.Mkael SymmondsNicholas D WrightElizabeth FaganRaymond J DolanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e68177 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mkael Symmonds Nicholas D Wright Elizabeth Fagan Raymond J Dolan Assaying the effect of levodopa on the evaluation of risk in healthy humans.
description	In humans, dopamine is implicated in reward and risk-based decision-making. However, the specific effects of dopamine augmentation on risk evaluation are unclear. Here we sought to measure the effect of 100 mg oral levodopa, which enhances synaptic release of dopamine, on choice behaviour in healthy humans. We use a paradigm without feedback or learning, which solely isolates effects on risk evaluation. We present two studies (n = 20; n = 20) employing a randomised, placebo-controlled, within-subjects design. We manipulated different dimensions of risk in a controlled economic paradigm. We test effects on risk-reward tradeoffs, assaying both aversion to variance (the spread of possible outcomes) and preference for relative losses and gains (asymmetry of outcomes--skewness), dissociating this from potential non-specific effects on choice randomness using behavioural modelling. There were no systematic effects of levodopa on risk attitudes, either for variance or skewness. However, there was a drift towards more risk-averse behaviour over time, indicating that this paradigm was sensitive to detect changes in risk-preferences. These findings suggest that levodopa administration does not change the evaluation of risk. One possible reason is that dopaminergic influences on decision making may be due to changing the response to reward feedback.
format	article
author	Mkael Symmonds Nicholas D Wright Elizabeth Fagan Raymond J Dolan
author_facet	Mkael Symmonds Nicholas D Wright Elizabeth Fagan Raymond J Dolan
author_sort	Mkael Symmonds
title	Assaying the effect of levodopa on the evaluation of risk in healthy humans.
title_short	Assaying the effect of levodopa on the evaluation of risk in healthy humans.
title_full	Assaying the effect of levodopa on the evaluation of risk in healthy humans.
title_fullStr	Assaying the effect of levodopa on the evaluation of risk in healthy humans.
title_full_unstemmed	Assaying the effect of levodopa on the evaluation of risk in healthy humans.
title_sort	assaying the effect of levodopa on the evaluation of risk in healthy humans.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/77b8e3e653ee486e9a0f48ed4d20fcd7
work_keys_str_mv	AT mkaelsymmonds assayingtheeffectoflevodopaontheevaluationofriskinhealthyhumans AT nicholasdwright assayingtheeffectoflevodopaontheevaluationofriskinhealthyhumans AT elizabethfagan assayingtheeffectoflevodopaontheevaluationofriskinhealthyhumans AT raymondjdolan assayingtheeffectoflevodopaontheevaluationofriskinhealthyhumans
_version_	1718423169235156992

Assaying the effect of levodopa on the evaluation of risk in healthy humans.

Ejemplares similares